Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT

被引：14

作者：

Engler, Tobias ^{[1
]}

Fasching, Peter A. ^{[2
]}

Lueftner, Diana ^{[3
,4
]}

Hartkopf, Andreas D. ^{[5
]}

Mueller, Volkmar ^{[6
]}

Kolberg, Hans-Christian ^{[7
]}

Hadji, Peyman ^{[8
,9
]}

Tesch, Hans ^{[10
]}

Haeberle, Lothar ^{[2
,11
]}

Ettl, Johannes ^{[12
]}

Wallwiener, Markus ^{[13
]}

Beckmann, Matthias W. ^{[2
]}

Hein, Alexander ^{[2
]}

Belleville, Erik ^{[14
]}

Uhrig, Sabrina ^{[2
]}

Wimberger, Pauline ^{[15
,16
,17
,18
,19
,20
,21
]}

Hielscher, Carsten ^{[22
]}

Kurbacher, Christian M. ^{[23
]}

Wuerstlein, Rachel ^{[24
,25
]}

Untch, Michael ^{[26
]}

Taran, Florin-Andrei ^{[27
]}

Enzinger, Hans-Martin ^{[28
]}

Krabisch, Petra ^{[29
]}

Welslau, Manfred ^{[30
]}

Maasberg, Michael ^{[31
]}

Hempel, Dirk ^{[32
]}

Lux, Michael P. ^{[33
,34
,35
]}

Michel, Laura L. ^{[36
]}

Janni, Wolfgang ^{[5
]}

Wallwiener, Diethelm ^{[1
]}

Brucker, Sara Y. ^{[1
]}

Fehm, Tanja N. ^{[37
]}

Schneeweiss, Andreas ^{[36
]}

机构：

[1] Univ Tubingen, Dept Obstet & Gynecol, Tubingen, Germany

[2] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen Univ Hosp, Comprehens Canc Ctr Erlangen EMN, Dept Gynecol & Obstet, Univ Str 21-23, D-91054 Erlangen, Germany

[3] Immanuel Hosp Mark Schweiz, Brandenburg, Germany

[4] Med Univ Brandenburg Theodor Fontane, Brandenburg, Germany

[5] Ulm Univ Hosp, Dept Gynecol & Obstet, Ulm, Germany

[6] Hamburg Eppendorf Univ Med Ctr, Dept Gynecol, Hamburg, Germany

[7] Marienhosp Bottrop, Dept Gynecol & Obstet, Bottrop, Germany

[8] Frankfurt Ctr Bone Hlth, Marburg, Germany

[9] Philips Univ Marburg, Marburg, Germany

[10] Bethanien Hosp, Oncol Practice, Frankfurt, Germany

[11] Erlangen Univ Hosp, Dept Gynecol & Obstet, Biostat Unit, Erlangen, Germany

[12] Tech Univ Munich, Dept Obstet & Gynecol, Klinikum Rechts Isar, Munich, Germany

[13] Heidelberg Univ Hosp, Dept Obstet & Gynecol, Heidelberg, Germany

[14] ClinSol GmbH & Co KG, Wurzburg, Germany

[15] Tech Univ Dresden, Dept Gynecol & Obstet, Carl Gustav Carus Fac Med, Dresden, Germany

[16] Tech Univ Dresden, Univ Hosp, Dresden, Germany

[17] Natl Ctr Tumor Dis NCT, Dresden, Germany

[18] German Canc Res Ctr, Heidelberg, Germany

[19] Tech Univ Dresden, Carl Gustav Carus Fac Med, Dresden, Germany

[20] Helmholtz Zentrum Dresden Rossendorf HZDR, Dresden, Germany

[21] German Canc Consortium DKTK, Dresden, Germany

[22] Onkol Zentrum Stralsund, Gynakol Kompetenzzentrum, Stralsund, Germany

[23] Gynecol Ctr Bonn, Dept Gynecol & Gynecol Oncol, Friedenspl, Bonn, Germany

[24] Munich Univ Hosp, Breast Ctr, Dept Gynecol & Obstet, Munich, Germany

[25] Munich Univ Hosp, CCC Munich, Munich, Germany

[26] Helios Clin Berlin Buch, Dept Gynecol & Obstet, Berlin, Germany

[27] Freiburg Univ Hosp, Dept Obstet & Gynecol, Freiburg, Germany

[28] Klinikum Bamberg, Sozialstiftung Bamberg, Dept Gynecol & Obstet, Bamberg, Germany

[29] Klinikum Chemnitz gGmbH, Dept Gynecol & Obstet, Chemnitz, Germany

[30] Onkol Aschaffenburg, Aschaffenburg, Germany

[31] MVZ Hamatol Onkol Mayen Koblenz GmbH, Mayen, Germany

[32] Onkol Zentrum Donauworth, Donauworth, Germany

[33] Frauenklin St Louise, Dept Gynecol & Obstet, Paderborn, Germany

[34] St Josefs Hosp, Frauenklin, Salzkotten, Germany

[35] St Vincenz Krankenhaus GmbH, Kooperat Brustzentrum Paderborn, Paderborn, Germany

[36] Heidelberg Univ Hosp, Natl Ctr Tumor Dis, German Canc Res Ctr DKFZ, Heidelberg, Germany

[37] Dusseldorf Univ Hosp, Dept Gynecol & Obstet, Dusseldorf, Germany

来源：

GEBURTSHILFE UND FRAUENHEILKUNDE | 2022年 / 82卷 / 10期

关键词：

advanced breast cancer; real world data; chemotherapy; CDK4/6; inhibitor; endocrine treatment; ENDOCRINE THERAPY; PALBOCICLIB; RIBOCICLIB; SURVIVAL; FULVESTRANT; LETROZOLE; ABEMACICLIB; COMBINATION; PROGRESSION; PATTERNS;

D O I：

10.1055/a-1880-0087

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Background Comprehensive data from prospective clinical trials have led to a high level of evidence establishing CDK4/6 inhibitors in combination with endocrine treatment (CDK4/6i + ET) as a standard for the treatment of HER2-negative, hormone receptor-positive (HER2- HR+) breast cancer patients in the first-line advanced therapy setting. Data on patient populations that have been treated in the real-world setting may provide an insight into changes of patient characteristics and prognosis over time. Methods The data were extracted from the prospective real-world registry PRAEGNANT (NCT02338167). Patients had to have HER2- HR+ advanced breast cancer in the first-line metastatic setting. The chosen therapies were described as well as progression-free survival (PFS) and overall survival (OS) in relation to the given therapies and time periods during which they were indicated. Results CDK4/6 inhibitors have been rapidly implemented since their introduction in November 2016. In recent years (2018-2022), about 70-80% of the patient population have been treated with CDK4/6 inhibitors, while endocrine monotherapy was given to about 10% and chemotherapy to about 15% of all patients. The prognosis was worst in patients treated with chemotherapy. Recently, mainly patients with a good prognosis are being treated with endocrine monotherapy, and patients who are treated with chemotherapy have an unfavorable prognosis. The PFS and OS of patients treated with CDK4/6i + ET have remained similar over time despite changes in patient characteristics. Conclusion A treatment with CDK4/6i + ET has rapidly become the therapy standard for patients in the first-line advanced breast cancer setting. After the implementation of CDK4/6i + ET, endocrine monotherapy is only given to patients with a very favorable prognosis, while chemotherapy is provided to patients with a rather unfavorable prognosis. These changes in patient characteristics did not seem to influence the prognosis of patients treated with CDK4/6i + ET.

引用

页码：1055 / 1067

页数：13

共 49 条

[31] In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium [J].

Lobbezoo, D. J. A. ;

van Kampen, R. J. W. ;

Voogd, A. C. ;

Dercksen, M. W. ;

van den Berkmortel, F. ;

Smilde, T. J. ;

van de Wouw, A. J. ;

Peters, F. P. J. ;

van Riel, J. M. G. H. ;

Peters, N. A. J. B. ;

de Boer, M. ;

Peer, P. G. M. ;

Tjan-Heijnen, V. C. G. .

ANNALS OF ONCOLOGY, 2016, 27 (02) :256-262

[32] Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP) [J].

Manso, Luis ;

Hernando, Cristina ;

Galan, Maria ;

Oliveira, Mafalda ;

Cabrera, Miguel A. ;

Bratos, Raquel ;

Rodriguez, Cesar A. ;

Ruiz-Borrego, Manuel ;

Blanch, Salvador ;

Llombart-Cussac, Antonio ;

Delgado-Mingorance, Juan I. ;

Alvarez-Busto, Inaki ;

Gallegos, Isabel ;

Gonzalez-Cortijo, Lucia ;

Morales, Serafin ;

Aguirre, Elena ;

Hernando, Blanca A. ;

Ballesteros, Ana ;

Ales-Martinez, Jose E. ;

Reboredo, Cristina ;

Oltra, Amparo ;

Gonzalez-Cao, Maria ;

Santisteban, Marta ;

Malon, Diego ;

Echeverria, Isabel ;

Garcia-Garre, Elisa ;

Vega, Estela ;

Servitja, Sonia ;

Andres, Raquel ;

Robles, Carlos E. ;

Lopez, Rafael ;

Galve, Elena ;

Echarri, Maria J. ;

Legeren, Marta ;

Moreno, Fernando .

BREAST, 2020, 54 :286-292

[33] Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL [J].

Martin, M. ;

Zielinski, C. ;

Ruiz-Borrego, M. ;

Carrasco, E. ;

Turner, N. ;

Ciruelos, E. M. ;

Munoz, M. ;

Bermejo, B. ;

Margeli, M. ;

Anton, A. ;

Kahan, Z. ;

Csoszi, T. ;

Casas, M., I ;

Murillo, L. ;

Morales, S. ;

Alba, E. ;

Gal-Yam, E. ;

Guerrero-Zotano, A. ;

Calvo, L. ;

de la Haba-Rodriguez, J. ;

Ramos, M. ;

Alvarez, I ;

Garcia-Palomo, A. ;

Bartlett, C. Huang ;

Koehler, M. ;

Caballero, R. ;

Corsaro, M. ;

Huang, X. ;

Garcia-Saenz, J. A. ;

Chacon, J., I ;

Swift, C. ;

Thallinger, C. ;

Gil-Gil, M. .

ANNALS OF ONCOLOGY, 2021, 32 (04) :488-499

[34] Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry [J].

Mueller, Volkmar ;

Nabieva, Naiba ;

Haeberle, Lothar ;

Taran, Florin-Andrei ;

Hartkopf, Andreas D. ;

Volz, Bernhard ;

Overkamp, Friedrich ;

Brandl, Anna Lisa ;

Kolberg, Hans-Christian ;

Hadji, Peyman ;

Tesch, Hans ;

Ettl, Johannes ;

Lux, Michael P. ;

Lueftner, Diana ;

Belleville, Erik ;

Fasching, Peter A. ;

Janni, Wolfgang ;

Beckmann, Matthias W. ;

Wimberger, Pauline ;

Hielscher, Carsten ;

Fehm, Tanja N. ;

Brucker, Sara Y. ;

Wallwiener, Diethelm ;

Schneeweiss, Andreas ;

Wallwiener, Markus .

BREAST, 2018, 37 :154-160

[35] A deep dive into CDK4/6 inhibitors: Evaluating real world toxicities and treatment paradigms in the elderly population [J].

Olazagasti, Coral ;

Lee, Chung-Shien ;

Liu, Angel ;

Stefanov, Dimitre ;

Cheng, Kit .

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) :14-21

[36] Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies [J].

Salmen, Jessica ;

Neugebauer, Julia ;

Fasching, Peter A. ;

Haeberle, Lothar ;

Huober, Jens ;

Woeckel, Achim ;

Rauh, Claudia ;

Schuetz, Florian ;

Weissenbacher, Tobias ;

Kost, Bernd ;

Stickeler, Elmar ;

Klar, Maximilian ;

Orlowska-Volk, Marzenna ;

Windfuhr-Blum, Marisa ;

Heil, Joerg ;

Rom, Joachim ;

Sohn, Christof ;

Fehm, Tanja ;

Mohrmann, Svjetlana ;

Loehberg, Christian R. ;

Hein, Alexander ;

Schulz-Wendtland, Ruediger ;

Hartkopf, Andreas D. ;

Brucker, Sara Y. ;

Wallwiener, Diethelm ;

Friese, Klaus ;

Hartmann, Arndt ;

Beckmann, Matthias W. ;

Janni, Wolfgang ;

Rack, Brigitte .

BREAST CANCER RESEARCH AND TREATMENT, 2014, 148 (01) :143-151

[37] Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany [J].

Schneeweiss, Andreas ;

Ettl, Johannes ;

Lueftner, Diana ;

Beckmann, Matthias W. ;

Belleville, Erik ;

Fasching, Peter A. ;

Fehm, Tanja N. ;

Geberth, Matthias ;

Haberle, Lothar ;

Hadji, Peyman ;

Hartkopf, Andreas D. ;

Hielscher, Carsten ;

Huober, Jens ;

Ruckhaberle, Eugen ;

Janni, Wolfgang ;

Kolberg, Hans Christian ;

Kurbacher, Christian M. ;

Klein, Evelyn ;

Lux, Michael P. ;

Mueller, Volkmar ;

Nabieva, Naiba ;

Overkamp, Friedrich ;

Tesch, Hans ;

Laakmann, Elena ;

Taran, Florin-Andrei ;

Seitz, Julia ;

Thomssen, Christoph ;

Untch, Michael ;

Wimberger, Pauline ;

Wuerstlein, Rachel ;

Volz, Bernhard ;

Wallwiener, Diethelm ;

Wallwiener, Markus ;

Brucker, Sara Y. .

BREAST, 2020, 54 :88-95

[38] Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer [J].

Slamon, Dennis J. ;

Neven, Patrick ;

Chia, Stephen ;

Fasching, Peter A. ;

De Laurentiis, Michelino ;

Im, Seock-Ah ;

Petrakova, Katarina ;

Bianchi, Giulia V. ;

Esteva, Francisco J. ;

Martin, Miguel ;

Nusch, Arnd ;

Sonke, Gabe S. ;

De la Cruz-Merino, Luis ;

Beck, J. Thaddeus ;

Pivot, Xavier ;

Sondhi, Manu ;

Wang, Yingbo ;

Chakravartty, Arunava ;

Rodriguez-Lorenc, Karen ;

Taran, Tetiana ;

Jerusalem, Guy .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (06) :514-524

[39] Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 [J].

Slamon, Dennis J. ;

Neven, Patrick ;

Chia, Stephen ;

Fasching, Peter A. ;

De Laurentiis, Michelino ;

Im, Seock-Ah ;

Petrakova, Katarina ;

Bianchi, Giulia Val ;

Esteva, Francisco J. ;

Martin, Miguel ;

Nusch, Arnd ;

Sonke, Gabe S. ;

De la Cruz-Merino, Luis ;

Beck, J. Thaddeus ;

Pivot, Xavier ;

Vidam, Gena ;

Wang, Yingbo ;

Lorenc, Karen Rodriguez ;

Miller, Michelle ;

Taran, Tetiana ;

Jerusalem, Guy .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (24) :2465-+

[40]

Slamon DJ, 2019, ANN ONCOL, V30, pv856, DOI [10.1093/annonc/mdz394.007, DOI 10.1093/ANNONC/MDZ394.007]

← 1 2 3 4 5 →